SOURCE: Vernalis PLC

June 30, 2015 09:38 ET

Vernalis plc - Appointment of Non-Executive Director

WINNERSH, UNITED KINGDOM--(Marketwired - Jun 30, 2015) - Vernalis plc (LSE: VER) (OTC PINK: VNLPY) announces that Dr Ian David Gilham, aged 55, has been appointed to the Board as a Non-Executive Director with effect from 1 July 2015. Dr Gilham will also serve as Chairman of the Company's Remuneration Committee.

Dr Gilham has international experience in the research, development and commercialisation of diagnostic and pharmaceutical products. He is Non-Executive Chairman of a number of UK and European companies including Epistem Holdings Limited, Concepta Diagnostics Limited, Horizon Discovery Group plc, Multiplicom NV, and Biosurfit SA. Dr Gilham was formerly CEO of Axis-Sheild plc, a FTSE listed global diagnostics company. He also previously worked at GlaxoSmithKline as Vice President - Pharmacogenetics and before that held international general management, marketing business development and R&D positions with Abbott Laboratories, Celltech and Amersham.

Peter Fellner, Chairman of Vernalis plc, commented:

"I am delighted to welcome Ian to the Vernalis Board. His depth of experience in the global pharmaceutical industry will be very valuable for the Board, and we look forward to his contribution, as we continue to build value for Vernalis' shareholders."

Disclosures:
Dr Gilham is a director or has been a director of the following companies during the previous five years:

     
Current directorships/partnerships   Director/Partner in the last 5 years
Concepta Diagnostics Ltd
Epistem Holdings Plc
Horizon Discovery Group Plc
Multiplicom NV
Biosurfit SA
Stowhealth Ltd
  Axis-Shield Plc
     

Other than as set out above there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Dr Gilham's appointment with effect from 1 July 2015 as a Non-Executive Director of the Company.

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has two approved products; Tuzistra™ XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

Contact Information

  • Enquiries:
    Vernalis plc:
    +44 (0) 118 938 0015
    Ian Garland
    Chief Executive Officer
    David Mackney
    Chief Financial Officer

    Canaccord Genuity Limited (Nominated Adviser):
    +44 (0) 20 7523 8350
    Dr Julian Feneley
    Peter Stewart
    Pippa Underwood

    Shore Capital (Joint Broker):
    +44 (0) 20 7408 4090
    Bidhi Bhoma
    Toby Gibbs

    Brunswick Group:
    +44 (0) 20 7404 5959
    Jon Coles